

CORRIGENDUM

Corrigendum to ‘Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study’



[ESMO Open Volume 6, Issue 4, August 2021, 100191]

K. Hotta^{1,2*}, S. Saeki³, M. Yamaguchi⁴, D. Harada⁵, A. Bessho⁶, K. Tanaka⁷, K. Inoue⁸, K. Gemba⁹, M. Shiojiri^{6,10}, Y. Kato^{1,2}, T. Ninomiya^{2,5}, T. Kubo², J. Kishimoto¹¹, Y. Shioyama¹², K. Katsui¹³, J. Sasaki¹⁴, K. Kiura² & K. Sugio¹⁵

¹Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama; ²Department of Respiratory Medicine, Okayama University Hospital, Okayama; ³Department of Respiratory Medicine, Kumamoto University Hospital, Kumamoto; ⁴Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Kyushu; ⁵Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Shikoku; ⁶Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama; ⁷Department of Respiratory Medicine, Kyushu University Hospital, Fukuoka; ⁸Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kitakyushu; ⁹Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama; ¹⁰Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Ehime; ¹¹Center for Clinical and Translational Research, Kyushu University Hospital, Kyushu; ¹²Clinical Radiology, Radiology Informatics and Network, Graduate School of Medical Sciences, Kyushu University, Kyushu; ¹³Department of Proton Beam Therapy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama; ¹⁴Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Kitasato; ¹⁵Department of Thoracic and Breast Surgery, Oita University, Oita, Japan

The authors regret that despite our best care and attention, we have discovered one error in text and corresponding errors in Table 3 and Supplementary Table S2.

1) One error, placed in the “Toxicity” paragraph in Results section has now been corrected as follows:

“Radiation pneumonitis, the most clinically important toxicity, occurred in 14 (82%; grade 1) and 2 (12%; grade 2) patients; ...”.

2) In Table 3, number and proportion of those with any grade radiation pneumonitis in CRT phase have also been corrected as “16 (94)”.

3) Supplementary Table S2 has also been corrected, according to the former correction of number of patients who had pneumonitis events from 14 to 16.

The authors would like to apologize for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.esmoop.2021.100191>

*Correspondence to: Dr Katsuyuki Hotta

E-mail: khotta@okayamau.ac.jp (K. Hotta).

2059-7029/© 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. All rights reserved.